Early Alzheimer’s neuron data reported by NeuroSense (NRSN) in 6-K filing

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. filed a Form 6-K after issuing a press release on its Alzheimer’s program. The company reported that its drug candidate shows early signals of benefit in neurons derived from Alzheimer’s patients, suggesting a potentially encouraging effect at the cellular level, though still at an early research stage.

The company is also using this report to update its existing shelf and equity compensation registration statements. The Form 6-K, including only part of Exhibit 99.1 as specified, is incorporated by reference into NeuroSense’s Form S-8 and multiple Form F-3 registration statements, meaning those SEC documents now formally include the information contained in this submission.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2025

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-7996183
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

On September 10, 2025, NeuroSense Therapeutics Ltd. issued a press release reporting that it’s drug candidate shows early signals of benefit in Alzheimer's patient-derived neurons. A copy of the press release is furnished herewith as Exhibit 99.1.

This Report on Form 6-K (including in Exhibit 99.1 only the language prior to the reference to Mr. Alon-Ben Noon) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-262480) and Form F-3 (File No. 333-269306, 333-260338, 333-283656 and 333-284051), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: September 10, 2025	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2

FAQ

What did NeuroSense Therapeutics (NRSN) disclose in this Form 6-K?

NeuroSense Therapeutics disclosed that it issued a press release reporting its Alzheimer’s drug candidate shows early signals of benefit in patient-derived neurons, and it incorporated this information into existing SEC registration statements.

What progress did NeuroSense (NRSN) report on its Alzheimer’s drug candidate?

The company reported that its drug candidate shows early signals of benefit in neurons derived from Alzheimer’s patients, based on preclinical cellular data described in the referenced press release.

How is this Form 6-K used in NeuroSense’s (NRSN) SEC registrations?

The Form 6-K, including part of Exhibit 99.1, is incorporated by reference into NeuroSense’s Form S-8 and several Form F-3 registration statements, so those filings now include this new information.

Does the NeuroSense (NRSN) Form 6-K include the full Alzheimer’s press release?

The Form 6-K furnishes the press release as Exhibit 99.1, but only the language before the reference to Mr. Alon Ben-Noon is incorporated by reference into the company’s registration statements.

Is this NeuroSense (NRSN) 6-K about a financing or major transaction?

No, the Form 6-K primarily reports scientific progress on an Alzheimer’s drug candidate and updates the company’s existing registration statements by incorporating this information by reference.

Who signed the NeuroSense Therapeutics (NRSN) Form 6-K?

The Form 6-K was signed on behalf of NeuroSense Therapeutics Ltd. by Alon Ben-Noon, the company’s Chief Executive Officer.